--- title: Cardiology Research Dubrava Prospective Registry nct_id: NCT06090591 overall_status: RECRUITING sponsor: University Hospital Dubrava study_type: OBSERVATIONAL primary_condition: Heart Failure countries: Croatia canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06090591.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06090591" ct_last_update_post_date: 2024-03-19 last_seen_at: "2026-05-12T06:04:52.685Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Cardiology Research Dubrava Prospective Registry **Official Title:** Cardiology Research Dubrava: Single Centre, Prospective Registry **NCT ID:** [NCT06090591](https://clinicaltrials.gov/study/NCT06090591) ## Key Facts - **Status:** RECRUITING - **Study Type:** OBSERVATIONAL - **Target Enrollment:** 3000 - **Lead Sponsor:** University Hospital Dubrava - **Conditions:** Heart Failure, Arrhythmias, Cardiac, Atrial Fibrillation, Acute Coronary Syndrome - **Start Date:** 2023-01-01 - **Completion Date:** 2033-06 - **CT.gov Last Update:** 2024-03-19 ## Brief Summary Cardiology Research Dubrava registry is a prospective, single centre registry including patients with acute coronary syndrome with and without ST segment elevation, patients with heart failure who were prescribed with SGLT-2 inhibitors, patients implanted with TAVI, patients with venous thromboembolism, patients with pulmonary embolism who underwent thromboaspiration procedure, patients implanted with ICD, CRT and conduction system pacing devices, as well as patients with atrial fibrillation who underwent pulmonary vein isolation and are prescribed with long-term anticoagulation therapy. ## Detailed Description Cardiology Research Dubrava registry is a prospective, single centre registry including patients with acute coronary syndrome with and without ST segment elevation, patients with heart failure who were prescribed with SGLT-2 inhibitors, patients implanted with TAVI, patients with venous thromboembolism, patients with pulmonary embolism who underwent thromboaspiration procedure, patients implanted with ICD, CRT and conduction system pacing devices, as well as patients with atrial fibrillation who underwent pulmonary vein isolation and are prescribed with long-term anticoagulation therapy. In this long-term follow-up registry we plan to collect data on clinical status, standard laboratory results including lipidogram values, NTproBNP values after specific interventions (in.ex. TAVI implantation, SGLT2inh prescripition), bleeding complications, and every major cardiovascular event, including cardiovascular death and all cause death. ## Eligibility - **Minimum age:** 18 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: patients implanted with CIED, or with VTE, or with ACS or with TAVI - Exclusion Criteria: non compliance, not undergoing follow-up at this center \- ``` ## Arms - **Acute coronary syndrome - ACS** — patients who were diagnosed with acute coronary syndrome: STEMI, non-STE ACS - NSTEMI and unstable angina, who underwent coronary angiography and were prescribed with optimal medicament therapy - **Transcatheter aortic valve implantation - TAVI** — patients with aortic stenosis who underwent transcatheter percotaneous implantation of the arteficial aortic valve - **Venous thromboembolism - VTE** — patients with pulmonary embolism and deep vein thrombosis, with a focus on those who underwent thromboaspiration due to high or medium-high risk pulmonary embolism - **Heart failure with SGLT2 inhibitor therapy included - HF-SGLT2** — patients with heart failure with reduced, mid-reduced and preserved systolic function who were prescribed with a SGLT-2 inhibitor therapy, and other optimal medicament therapy for HF - **Cardiac implantable electronic device - CIED** — patients who were implanted with a cardiac implantable electronic device: pacemaker, conduction system pacing device, cardioverter-defibrilator or cardiac resynchronization therapy with or without defibrilator option - **Arrhythmias** — patients who underwent electrophysiology study, including PVI for atrial fibrillation, as well as SVT ablations, and ventricular arrhythmia ablation (both premature ventriclar beats and ventricular tachycardia ablation in ischsmic and non-ischemic cardiomyopathy). ## Interventions - **SGLT-2 inh therapy, CIED implantation, thromboaspiration,** (OTHER) — long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital ## Primary Outcomes - **cardiovascular death** _(time frame: 10 years)_ — death due to cardiovascular etiology during long term follow-up - **freedom from atrial arrhythmias** _(time frame: 10 years)_ — Freedom from atrial arrhythmias after PVI during mid-term folow-up (1 year) and long-term follow-up - **Time to revascularization** _(time frame: 10 years)_ — Time to revascularization during acute coronary syndrome - **Bleeding complications** _(time frame: 10 years)_ — Bleeding complications during long-term follow-up in patients prescribed with oral anticoagulation and/or antithrombotic therapy - **Laboratory levels of NTproBNP** _(time frame: 10 years)_ — Laboratory levels of NTproBNP in patients with AFib after PVI, in patients with HF prescribed with SGLT2 inhibitors, in patients with ACS after complete revasculariazation, in patients implanted with CIED ## Locations (1) - Dubrava University Hospital, Zagreb, Croatia — _RECRUITING_ ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.dubrava university hospital|zagreb||croatia` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT06090591.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT06090591* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*